ReviewMaterials today. Bio2025
Leveraging polysaccharide-derived nanocarriers to open new horizons in oral vaccine activation.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Orally activatable membrane fusion-mitochondria hitchhiking on intestinal macrophages for targeted therapy of bacterial meningitis and neuroinflammation.Bioactive materials · 2027Article
- Nano-adjuvants enhance the immunogenicity and safety of infectious bursal disease virus vaccines: a comprehensive review.Frontiers in immunology · 2026Review
- Herbal polysaccharides-a rising star in engineering multifunctional biomaterials for tissue repair and regeneration.Regenerative biomaterials · 2026Review
- Rethinking delivery routes: oral administration of plant-derived exosome-like nanovesicles reduces the toxicity of intravenous injection.Extracellular vesicles and circulating nucleic acids · 2026Article
- Nanobiotic-Enhanced Probiotics for Targeted Gut Delivery: Mechanisms, Therapeutic Applications, and Translational Challenges.International journal of nanomedicine · 2026Review
- Agricultural and Agro-Industrial Residues as Sustainable Sources of Next-Generation Biomedical Materials: Advances, Challenges, and Perspectives.Life (Basel, Switzerland) · 2025Review
- Polymeric particle-based antigen delivery system: From immunological engineering to clinical translation.International journal of pharmaceutics: X · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral vaccines represent a transformative approach in immunization, offering non-invasive administration, mucosal immune activation, and improved patient compliance. However, their clinical translation is hindered by multiple physiological barriers, such as gastric degradation, enzymatic hydrolysis, and inefficient antigen uptake in gut-associated lymphoid tissues. This review explores the emerging role of polysaccharide-derived nanocarriers, particularly those inspired by traditional Chinese medicine (TCM), in addressing these challenges. We discuss how these biocompatible and biodegradable materials can be engineered to enhance antigen stability, promote targeted delivery to Peyer's patches, and stimulate robust mucosal and systemic immune responses. Key design principles-such as bioadhesion, structural tunability, and immunomodulatory capacity-are highlighted across various carrier systems. Moreover, we examine multifunctional delivery strategies, including co-delivery of adjuvants, pH-responsive release, and mucoadhesive platforms. Special emphasis is placed on the potential integration of polysaccharide nanocarriers into next-generation oral mRNA and nucleic acid vaccine technologies. These insights underscore the promise of polysaccharide-based nanotechnology as a cornerstone for future oral vaccine platforms, paving the way for non-invasive, scalable, and immunologically effective vaccination strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.